Pacer Advisors Inc. Buys New Holdings in Insmed, Inc. $INSM

Pacer Advisors Inc. purchased a new position in shares of Insmed, Inc. (NASDAQ:INSM) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 15,583 shares of the biopharmaceutical company’s stock, valued at approximately $2,712,000.

A number of other institutional investors have also recently bought and sold shares of INSM. Vanguard Group Inc. lifted its position in shares of Insmed by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock valued at $3,668,127,000 after buying an additional 1,140,524 shares during the last quarter. Darwin Global Management Ltd. increased its holdings in shares of Insmed by 2.3% during the 4th quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock worth $3,644,274,000 after acquiring an additional 475,832 shares during the last quarter. Capital International Investors raised its stake in Insmed by 1.0% in the 3rd quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock valued at $1,087,830,000 after acquiring an additional 74,994 shares during the period. State Street Corp raised its stake in Insmed by 30.6% in the 4th quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock valued at $905,312,000 after acquiring an additional 1,217,390 shares during the period. Finally, Artisan Partners Limited Partnership lifted its holdings in Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after purchasing an additional 1,623,342 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Guggenheim reduced their price objective on shares of Insmed from $230.00 to $226.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Royal Bank Of Canada cut their target price on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Truist Financial reduced their target price on shares of Insmed from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Jefferies Financial Group began coverage on shares of Insmed in a research note on Monday, March 16th. They issued a “buy” rating and a $228.00 price target on the stock. Finally, Mizuho set a $192.00 target price on Insmed in a research report on Tuesday, June 16th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Insmed has a consensus rating of “Moderate Buy” and a consensus target price of $211.86.

Insider Buying and Selling at Insmed

In related news, CEO William Lewis sold 7,605 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total transaction of $777,763.35. Following the sale, the chief executive officer owned 265,432 shares of the company’s stock, valued at $27,145,730.64. This represents a 2.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Michael Alexander Smith sold 2,159 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $220,800.93. Following the transaction, the insider owned 39,454 shares in the company, valued at approximately $4,034,960.58. This trade represents a 5.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 149,783 shares of company stock valued at $22,902,672 in the last three months. Corporate insiders own 2.10% of the company’s stock.

Insmed Price Performance

NASDAQ:INSM opened at $102.15 on Wednesday. Insmed, Inc. has a 52 week low of $90.39 and a 52 week high of $212.75. The firm has a market cap of $22.14 billion, a price-to-earnings ratio of -17.77 and a beta of 0.79. The firm’s 50-day simple moving average is $115.70 and its 200 day simple moving average is $145.52. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The firm had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. During the same quarter in the previous year, the firm posted ($1.42) EPS. The business’s revenue for the quarter was up 229.7% compared to the same quarter last year. As a group, sell-side analysts predict that Insmed, Inc. will post -2.54 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.